Could a simple protein boost stroke recovery? new trial aims to find out
NCT ID NCT07294391
First seen Jan 11, 2026
Summary
This study tests whether giving a protein called albumin directly into the artery, right after a stroke clot is removed, can reduce brain damage. Sixty adults with large-vessel stroke will be randomly assigned to get either standard care alone or standard care plus albumin. The main goal is to see if albumin shrinks the area of brain injury measured on MRI scans 24 hours later.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE FROM LARGE VESSEL OCCLUSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
human albumin (a protein given into the artery)
What this could lead to
If it works, this could point toward a simple, safe way to limit brain damage after a stroke and improve recovery.
What could go wrong
This is a small, early-phase trial with only 60 people, so results may not apply widely. The benefit over standard care alone is uncertain, and there may be risks from the infusion itself.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.